Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
GE HealthCare has announced the launch of Pixxoscan (gadobutrol), a new Magnetic Resonance Imaging (MRI) contrast agent, expanding its portfolio alongside Clariscan (gadoteric acid). Pixxoscan shares the same active substance and formulation as the reference product, Gadovist, and is aimed at enhancing the accessibility of MRI procedures for radiology departments. Market authorization is already in place in Austria, with additional approvals expected in several European countries throughout 2023. Pixxoscan is indicated for various MRI applications, offering high relaxivity for improved visualization of tissues and abnormalities. The product will be available in multiple packaging options, enhancing convenience and reducing environmental impact.